In National Advertising Division Challenge, Medicine Center Pharmacy Voluntarily Discontinues Compounded Sublingual Semaglutide Product Claims
New York, NY, October 8, 2025 - BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk, Inc. regarding express and implied advertising claims made by Medicine Center Pharmacy (MCP) concerning the benefits, efficacy, and safety of its compounded sublingual semaglutide products that appeared on MCP’s website and social media pages.
During the inquiry, MCP informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
During the inquiry, MCP informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.